Data integrity … dil se Viveka Roychowdhury Jun 20, 2015 Two reports, released in early June, have both good news and bad news for the pharma industry in India
2015 USTR Special 301 Report Reactions and the way forward Viveka Roychowdhury Jun 9, 2015 In the aftermath of this year’s USTR Special 301 Report, which retained India on the Priority Watch List, industry leaders comment…
Wish list for PM Modi’s second year Viveka Roychowdhury May 27, 2015 Just as 2015 is a make or break year for PM Modi, this will be a decisive year for the pharma sector as well Now that the…
When patience is not a virtue Viveka Roychowdhury May 21, 2015 India once again made it to the Priority Watch list of the 2015 USTR Special 301 Report, but this year, the reaction from India’s…
Rebooting Jan Aushadhi Viveka Roychowdhury May 1, 2015 As Prime Minister Modi completes a year in office this May, there will no doubt be many lists of this government’s achievements…
Bullish on India Viveka Roychowdhury Apr 21, 2015 Since 2013, Novartis has sharpened focus, with last April's asset swaps with GSK and Eli Lilly the next step in this process. In…
Good growth prospects despite headwinds Viveka Roychowdhury Apr 21, 2015 As we settle into FY2016, it is worth taking a quick look at some of the earning previews of the last quarter
Making hay while the Sun shines Viveka Roychowdhury Mar 27, 2015 Success hinges on the company getting its GMP right and surviving the glare of regulatory scrutiny
Intent right, but implementation is key Viveka Roychowdhury Mar 20, 2015 Finance Minister Arun Jaitley’s first Union Budget had nothing special for the pharmaceutical industry
Govt to release policy to improve bulk drug capacity: Subburaj Viveka Roychowdhury Mar 6, 2015 Other topics at the ASSOCHAM Pharma Summit included changes in drug pricing, the impending revision of NLEM-2011, and amendments…